Business Wire

Oral OTEZLA®▼ (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis

Del

Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of OTEZLA (apremilast) for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to or have been unable to tolerate Disease Modifying Anti-Rheumatic Drugs (DMARDs).1 OTEZLA does not require pre-screening for tuberculosis or regular laboratory monitoring.2

Psoriatic arthritis is a chronic disease that causes significant strain on NHS resources,” said Dr Helena Marzo-Ortega, Honorary Senior Lecturer and Consultant at Leeds Teaching Hospitals NHS Trust. “Addressing the symptoms of both psoriasis and psoriatic arthritis, the availability of OTEZLA on the NHS marks a major milestone in the management of psoriatic arthritis.”

Psoriatic arthritis is a complex disease which involves multiple manifestations that can impact skin and joints and is most common in people aged 30 years to 50 years.3 It is estimated that over 296,000 people in the UK are affected by this incapacitating disease.4,5 Living with psoriatic arthritis can hinder a person’s ability to carry out simple everyday activities; from getting in or out of bed, to walking outdoors on flat ground.6

Following initial negative guidance issued by NICE in September 2015, OTEZLA was reappraised under the NICE Rapid Review process.1 OTEZLA, alone or in combination with DMARDs, is now recommended with a Patient Access Scheme for adults with active psoriatic arthritis when:

  • they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
  • their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination1

Today’s decision brings access for patients in England and Wales in line with those in Scotland, where OTEZLA was recommended by the Scottish Medicines Consortium (SMC) in June 2015.7

Dr Dani Thomas, Medical Director, Celgene UK & Ireland, commented: We are delighted that patients in England and Wales can now access OTEZLA via the NHS, bringing availability in line with patients in Scotland. OTEZLA’s novel mechanism of action and oral administration provides psoriatic arthritis patients with a much needed treatment option. Celgene will continue our dedication to develop and deliver innovative medicines for people affected by diseases where there is a high unmet need.

OTEZLA is an oral treatment for psoriatic arthritis that works by reducing the activity of an enzyme called phosphodiesterase 4 (PDE4), which is involved in the process of inflammation.8 By reducing the activity of this enzyme, OTEZLA can help to control the inflammation associated with psoriatic arthritis, and thereby reduce the signs and symptoms of the condition.9, 10

The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) programme is one of the largest global clinical development programmes ever conducted in psoriatic arthritis and it measured the efficacy and safety of OTEZLA.11 Across PALACE 1, 2 and 3, significantly more patients on OTEZLA achieved ACR20 at Week 16 than those on placebo.8

OTEZLA has demonstrated proven and durable efficacy in psoriatic arthritis, with improvement in swollen and tender joints, as well as pre-existing dactylitis (inflammation of fingers and toes, commonly known as “sausage fingers and toes”) and enthesitis (inflammation at sites where tendons or ligaments insert into bone) with a statistically significant improvement in physical function.8 The most common adverse reactions in Phase III clinical studies were diarrhoea and nausea. These adverse reactions generally occurred within the first two weeks of treatment and usually resolved within four weeks.2

– Ends –

NOTES TO EDITORS

About OTEZLA ®

OTEZLA® is an oral inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP).8 PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators.9,10

OTEZLA, alone or in combination with Disease Modifying Anti-Rheumatic Drugs (DMARDs), was approved by the European Medicines Agency in 2015 for the treatment of psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

OTEZLA was also licensed by the European Commission for the treatment of moderate to severe chronic plaque psoriasis in adult patients who do not respond to, have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).8

OTEZLA has a novel mechanism of action, offering a treatment option that does not require pre-screening for tuberculosis or regular laboratory tests.2 In clinical trials of psoriatic arthritis, treatment with OTEZLA demonstrated a statistically significant improvement in physical function vs. placebo as well as improving disease-related quality of life.12

The Summary of Product Characteristics is available here.

About Psoriatic Arthritis

Psoriatic arthritis is a painful, chronic inflammatory disease characterised by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and decrease in physical functioning.13 Psoriatic arthritis can impact the ability to perform day-to-day activities and has been reported to increase work disability.14,15 Enthesitis (inflammation at sites where tendons or ligaments insert into bone) and dactylitis (inflammation of fingers and toes, commonly known as “sausage digits”) are specific disease manifestations related to psoriatic arthritis.13 Up to 30% of people with psoriasis may also experience psoriatic arthritis.16

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene UK & Ireland is a subsidiary of Celgene Corporation. For more information, please visit

http://celgene.co.uk/.

Follow Celgene on Social Media: @CelgenePinterestLinkedIn and YouTube.

REFERENCES

1 NICE: Apremilast for the treatment of active psoriatic arthritis

2 Reich K et al. Long-term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate to Severe Psoriasis: Results from a Phase III, Randomized, Controlled Trial (ESTEEM 1). P8296. Presented at the 72nd Annual Meeting of the American Academy of Dermatology 2014; March 21-25; Denver, CO, USA

3 The Cleveland Clinic Foundation. Disease Management chapter on Psoriatic Arthritis by M. Elaine Husni. Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/rheumatology/psoriatic-arthritis/ Last accessed December 2016

4 Population estimates for UK, England and Wales, Scotland and Northern Ireland. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland Last accessed December 2016.

5 NICE: Costing statement: Implementing the NICE guidance on ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) (TA340). Published: May 2015

6 Lebwohl et al.Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 0190-9622

7 OTEZLA® Detailed Advice Document (DAD) https://www.scottishmedicines.org.uk/files/advice/apremilast__Otezla__plaque_psoriasis_FINAL_May_2015_REVI SED_010615_for_website.pdf Last accessed December 2016

8 OTEZLA® Summary of Product Characteristics. Current version available online at www.medicines.org.uk Last accessed December 2016

9 Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590

10 Schafer PH, et al. Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855

11 OTEZLA Clinical development program. Available at: https://www.otezla.net/psoriatic-arthritis/clinical-efficacy/study-design/ Last accessed December 2016

12 Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026

13 Gottlieb A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851 864

14 Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: A literature review from a global health systems perspective. P&T. 2010;35(12):680-689

15 Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology. 2012;51:275-283

16 National Institute for Health and Care Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: Technology appraisal guidance 199. August 2010

Contact information

Celgene UK & Ireland
Media:
Amanda Simonds
Senior Corporate Affairs and Patient Advocacy Manager
T. 020 8831 8672
asimonds@celgene.com
or
Celgene
Investors:
Patrick E. Flanigan III
Corporate Vice President, Investor Relations
T. +1 908 673 9969
pflanigan@celgene.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

TRIGO Deepens its Expansion into the USA by Acquiring Lumbee Enterprises23.7.2018 13:00Pressemelding

TRIGO has acquired 100% of the capital of Lumbee Enterprises based in Greer, SC. This acquisition allows TRIGO to deepen its expansion into the USA within the automotive industry. Lumbee began providing supply chain and logistics services over 25 years ago and it’s TRIGO’s intent to leverage Lumbee’s proven expertise to further expand its business. Lumbee is best known for its expertise in Quality Manufacturing, Sorting, Inspection and Sub-Assembly Operations, specializing in providing best-in-class inspection and rework services to keep OEM assembly lines running seamlessly and without interruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005040/en/ Co-founded by Colby Griffin in 2001, LUMBEE Enterprises of South Carolina has focused on providing quality management services to shorten supply chain interruptions through the innovative use of technology and processes. “This acquisition is a great opportunity for

STATS Taps Dr. Helen Sun, Former CTO of JPMorgan Chase Commercial Banking Division, to Lead STATS’ Technology Operations23.7.2018 11:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, expanded its executive roster with the introduction of Dr. Helen Sun as Chief Technology Officer. Sun will oversee STATS’ product, engineering, artificial intelligence and data production teams in developing the next generation of products and services that will revolutionize the performance and experience of sports. Sun joins STATS from JPMorgan Chase, most recently serving as Chief Technology Officer of the Commercial Banking division. For over 22 years, Sun has a proven record as a technology strategist and thought leader in previous roles as Vice President of Cloud Computing, Information Management, and Architecture at Motorola Solutions; Senior Director of Global Enterprise Architecture at Salesforce; and Director of Enterprise Architecture at Oracle. “Helen is a leader in transforming businesses through innovative solutions and she will be a driving force in building upon our reputation as the leading sports tech

IBC2018 Enhances Conference Programme with Keynote Sessions from Amazon, Viacom and Wonderhood Studios23.7.2018 10:57Pressemelding

IBC2018, the world’s most influential media, entertainment and technology show, today announces three new Keynote speakers from globally renowned media and entertainment powerhouses. The addition of executives from Amazon, Viacom and Wonderhood Studios adds to the big-name line up of thought provoking and informative sessions and speakers already announced by IBC. Taking to the stage on the first day of the conference, Thursday 13 September, to deliver the Trailblazer Keynote session entitled ‘Give Your Vision a Voice’ is Max Amordeluso, EU Lead Evangelist Amazon Alexa, Amazon. As voice assistants such as Amazon Alexa are transforming the way audiences discover content and control devices, Amordeluso’s must-attend presentation will explore a variety of avenues, including: how to build a voice strategy with Alexa; why voice experiences are now a crucial part of any multi-platform content business; how to implement an engaging voice strategy for content products and generate new revenues

SIGOS: Digital Experience - 120 mobile network operators from 60 countries meet in Nuremberg23.7.2018 10:06Pressemelding

For more than 10 years, SIGOS has been inviting mobile network operators from all over the world to the annual telecommunications conference. After venues such as Düsseldorf, Berlin, Munich, Beijing, Kuala Lumpur, etc., this year's multi-day conference took place at the Nuremberg convention centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005282/en/ SIGOS conference panel discussion - photo: www.uwe-niklas.com Over 120 network operators and telecommunications companies from over 60 countries worldwide came together to talk about the latest innovations in areas such as network quality, performance, 5G, IoT, roaming, and telecommunications fraud detection solutions. Dr. Ulrich Maly, Lord Mayor of the City of Nuremberg, welcomed the international audience in his opening speech and explained:"...when we talk about mobile communication, then we talk about people and their needs that are and should be the focus of atte

AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University22.7.2018 09:52Pressemelding

The American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, and the Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan, signed a Memorandum of Understanding (MoU), agreeing to exchange students, faculty, and research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180722005025/en/ The Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan and the American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, exchange a gift to commemorate their universities uniting in an MoU agreement. (Photo: AETOSWire) In the spirit of fostering a close international relationship between the Republic of Kazakhstan and the United Arab Emirates, developing bilateral relations in educational and scientific fields, and wishing to make their own contributions to the

Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.21.7.2018 18:19Pressemelding

The board of directors of Philip Morris International (NYSE:PM) has its board member, Sergio Marchionne, and his family in our thoughts and prayers during this challenging time. We congratulate our board chairman, Louis Camilleri, as he assumes the role of CEO of Ferrari S.p.A. The long term relationship between our two companies is deep and meaningful and we look forward to continued business collaboration. Mr. Camilleri will continue to serve as non-executive chairman of the PMI board. Philip Morris International: Who We Are We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirem